相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
The PROTAC technology in drug development
Yutian Zou et al.
CELL BIOCHEMISTRY AND FUNCTION (2019)
Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1
Joshua D. Hansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders
Scott J. Hughes et al.
STRUCTURE-BASED DRUG DESIGN: INSIGHTS FROM ACADEMIA AND INDUSTRY (2017)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Georg Petzold et al.
NATURE (2016)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Philip P. Chamberlain et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Improved side-chain torsion potentials for the Amber ff99SB protein force field
Kresten Lindorff-Larsen et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Thalidomide-induced limb defects: resolving a 50-year-old puzzle
Neil Vargesson
BIOESSAYS (2009)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
GROMACS: Fast, flexible, and free
D Van der Spoel et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors
ER Lepper et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia
RE Johnston et al.
LEUKEMIA & LYMPHOMA (2002)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
F Bertolini et al.
ANNALS OF ONCOLOGY (2001)
分享论文
